1. Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy

   • Markus Schwaiger
   • Christian Peschel

   OriginalPaper 16 May 2006 Pages: 1 - 5

2. Imaging biomarkers as surrogate endpoints for drug development

   • Wolf S. Richter

   ReviewPaper 24 May 2006 Pages: 6 - 10

3. Current standards for response evaluation by imaging techniques

   • S. J. Gwyther

     17 June 2006 Pages: 11 - 15

   

4. How should we analyse FDG PET studies for monitoring tumour response?

   • Adriaan A. Lammertsma
   • Corneline J. Hoekstra
   • Otto S. Hoekstra

     09 June 2006 Pages: 16 - 21

   

5. Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas

   • N. George Mikhaeel

   ReviewPaper 09 June 2006 Pages: 22 - 26

6. Monitoring chemotherapy and radiotherapy of solid tumors

   • Wolfgang A. Weber
   • Hinrich Wieder

   ReviewPaper 11 May 2006 Pages: 27 - 37

   

7. Is 3′-deoxy-3′-¹⁸F-fluorothymidine a better marker for tumour response than ¹⁸F-fluorodeoxyglucose?

   • Sven N. Reske
   • Sandra Deisenhofer

   ReviewPaper 24 May 2006 Pages: 38 - 43

   

8. Hypoxia imaging-directed radiation treatment planning

   • J.G. Rajendran
   • K.R.G. Hendrickson
   • D.A. Mankoff

   Original article 09 June 2006 Pages: 44 - 53

   

9. α_vβ₃-integrin imaging: a new approach to characterise angiogenesis?

   • Roland Haubner

   Original paper 22 June 2006 Pages: 54 - 63